Half-Dose Anticoagulation versus Antiplatelet Therapy to Reduce Silent Cerebral Embolism after Left Atrial Appendage Occlusion (HALO-SCE Study): Rationale and Design of a Randomized Clinical Trial
Cerebrovascular Diseases · 15.07.2025 · 55 (3) · 394-399
DOI: 10.1159/000547304 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cerebrovascular Diseases, online erschienen am 15.07.2025. Verfasst von Kexin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Atrial Appendage, Intracranial Embolism, Atrial Fibrillation, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Introduction
Patients with atrial fibrillation (AF) continue to face thrombotic risks even after the left atrial appendages have been occluded, which may manifest as silent cerebral embolisms (SCEs). Half-dose anticoagulation (Hd-OAC) is a pathophysiologically more reasonable therapy in addressing this issue than antithrombotic therapy, but it still lacks strong evidence.
Methods
The trial (NCT05671276) is a multicenter, randomized controlled trial comparing the efficacy of two antithrombotic strategies (Hd-OAC therapy vs. standard antithrombotic therapy) in AF patients after left atrial appendage occlusion (LAAO). The primary endpoint is the incidence of newly detected SCEs on any magnetic resonance imaging conducted during the follow-up period. The secondary endpoints are: (1) more than two new SCEs during the follow-up, their size, and distribution; (2) cognitive function, and (3) a composite endpoint of all-cause mortality, clinical thromboembolic events, and major bleeding events. Follow-up is scheduled at 90 ± 15 days, 180 ± 15 days, and 365 ± 15 days after LAAO.
Conclusions
This trial aimed to determine whether Hd-OAC therapy can reduce the incidence of SCE and protect cognitive function in patients who have successfully undergone LAAO, compared to standard antithrombotic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- Department of Cardiology, Affiliated Hospital of Nantong University, Nantong, China.
- Department of Cardiology, Taizhou People's Hospital, Taizhou, China.
- Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China, juweizhu@126.com.
Zitieren
APA
Wang, K., Shi, L., Ruan, Z., Jin, C., Li, M., Liu, H., Chen, H., Ju, W., & Chen, M. (2025). Half-Dose Anticoagulation versus Antiplatelet Therapy to Reduce Silent Cerebral Embolism after Left Atrial Appendage Occlusion (HALO-SCE Study): Rationale and Design of a Randomized Clinical Trial. Cerebrovascular Diseases, 55(3), 394-399. https://doi.org/10.1159/000547304
Vancouver
Wang K, Shi L, Ruan Z, Jin C, Li M, Liu H, et al. Half-Dose Anticoagulation versus Antiplatelet Therapy to Reduce Silent Cerebral Embolism after Left Atrial Appendage Occlusion (HALO-SCE Study): Rationale and Design of a Randomized Clinical Trial. Cerebrovascular Diseases. 2025;55(3):394-399. doi:10.1159/000547304
BibTeX
@article{Wang2025,
author = {Wang, Kexin and Shi, Linsheng and Ruan, Zhongbao and Jin, Caiyi and Li, Mingfang and Liu, Hailei and Chen, Hongwu and Ju, Weizhu and Chen, Minglong},
title = {Half-Dose Anticoagulation versus Antiplatelet Therapy to Reduce Silent Cerebral Embolism after Left Atrial Appendage Occlusion (HALO-SCE Study): Rationale and Design of a Randomized Clinical Trial},
journal = {Cerebrovascular Diseases},
year = {2025},
volume = {55},
number = {3},
pages = {394--399},
doi = {10.1159/000547304}
}
EUVIMED